Client Results

A diagnostic company wanted to assess the current and expected future landscapes for biopharma oncology genomics research and Dx / CDx

A leader in ctDNA testing was interested in investigating the opportunity for their assay to support treatment decision-making in 2 tumor types of interest (including 6 cancer subtypes)

A leader in research tools and clinical diagnostic development asked us to evaluate the opportunity for an ultrasensitive detection platform in methylation analysis

A real-world data (RWD) provider wanted to identify key use cases, unmet needs, and future opportunities in the RWD market, with a particular focus on clinical, genomic, and pathology RWD and biopharma users.

A leader in research and clinical sequencing wanted to assess the market opportunity and key customer segments for an in-house hereditary cancer testing (HCT) solution

A multi-billion dollar life science company needed pre diligence on a potential acquisition target

A cancer diagnostics company wanted to understand the current and future landscape for RNA-based oncology biomarkers, focusing on gene expression profiling (GEP) and rearrangements across medical settings

A large pharmaceutical company engaged DeciBio to evaluate strategies for an internal build of a lab to support clinical and commercial opportunities in oncology

A UK-based life science services provider was interested in learning more about the value and market landscape for synthetic mRNA production to inform a potential acquisition strategy

A large multi-national diagnostic company was interested in understanding the market landscape and potential strategy for the decentralization of NIPT in the U.S.

A healthcare technology startup wanted to conduct an assessment of potential go-to-market strategies for their AI analytical patient recruitment tool

A leading pharmaceutical & clinical diagnostics manufacturer wanted to understand the market opportunity for a novel multidisciplinary cancer conference IT support solution

The ventures arm of a top-20 U.S. health system sought support developing a go-to-market strategy for RWD-augmented biobank offerings

A global healthcare investment firm wanted to perform a commercial due diligence (CDD) prior to investment in a company producing a novel handheld diagnostic.

A global private equity firm wanted to project the revenues and competitive positioning of a leading oncology diagnostics provider to support a growth capital investment

A leading private equity firm and management team sought out DeciBio as a strategic partner to advise on the life sciences market and perform due-diligences in support of the development of a novel life sciences tools platform

A ~$100M research tools and diagnostic company wanted to understand key applications and revenue potential of their novel technology to inform a go / no-go development decision

A research tools start-up enlisted DeciBio to support their go-to-market strategy and activities for their novel sequencing technology by conducting pricing voice-of-customer research and evaluating potential pricing strategies

A multinational pharmaceutical and diagnostics company was interested in learning more about the U.S. market opportunity for their novel noninvasive prenatal test in development

A multi-billion dollar life science company needed pre diligence on a potential acquisition target

A leading diagnostics player asked DeciBio to characterize the evolving NIPT market to help inform strategic positioning regarding menu offerings and technological approach

A leading diagnostic company wanted an assessment of the future market landscape for low-throughput (LT) molecular diagnostic (MDx) testing to develop a long-term platform strategy to address the future needs of this market

A major diagnostics manufacturer had developed a novel technology for the rapid detection of infectious pathogens and required assistance in developing commercialization strategy and sales tactics. DeciBio’s services were contracted to profile relevant stakeholders, characterize existing workflows and acquisition / implementation processes, and develop a product-specific launch strategy.

A large life science tools provider was interested in characterizing the genome engineering and engineered cell line market to identify potential opportunities to participate in the space

A leading diagnostics player wanted an assessment of the current and future carrier screening landscape, primarily in the U.S., to guide their product development strategy